PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy
Drug delivery systems for cancer chemotherapy are employed to improve the effectiveness
and decrease the side-effects of highly toxic drugs. Most chemotherapy agents have …
and decrease the side-effects of highly toxic drugs. Most chemotherapy agents have …
[HTML][HTML] EGFR first-and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
N Karachaliou, M Fernandez-Bruno… - Translational Cancer …, 2019 - ncbi.nlm.nih.gov
Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study
Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui… - Cancer cell, 2021 - cell.com
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
LINC00173. v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression
J Chen, A Liu, Z Wang, B Wang, X Chai, W Lu, T Cao… - Molecular cancer, 2020 - Springer
Background Anti-angiogenic therapy represents a promising strategy for non-small-cell lung
cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to …
cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to …
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Q Sun, J Zhou, Z Zhang, M Guo, J Liang… - Cancer Biology & …, 2014 - Taylor & Francis
VEGF/VEGFR signal axis has been proven to be an important target for development of
novel cancer therapies. One challenging aspect in small molecular VEGFR inhibitors is to …
novel cancer therapies. One challenging aspect in small molecular VEGFR inhibitors is to …
Polymer assembly: Promising carriers as co-delivery systems for cancer therapy
N Li, L Zhao, L Qi, Z Li, Y Luan - Progress in Polymer Science, 2016 - Elsevier
Drug-delivery systems, including liposomes, polymeric micelles, polymersomes, hydrogels
and other formulations, have attracted much attention in recent years because they can …
and other formulations, have attracted much attention in recent years because they can …
Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results
T Kato, T Seto, M Nishio, K Goto, N Yamamoto… - Drug safety, 2018 - Springer
Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer
K Perdrizet, NB Leighl - Current treatment options in oncology, 2019 - Springer
Opinion statement The treatment of advanced non-small cell lung cancer (NSCLC) has
evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected …
evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected …
Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
K Zhou, S Zhao, W Guo, L Ding - Medicine, 2020 - journals.lww.com
Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …